Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID L JOHNSON

Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist

NPI
1811942527
CMS profile
127979
Location
WEST COLUMBIA, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$210.91

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $210.91 6

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Ocular Therapeutix, Inc. $96.66 1
Regeneron Healthcare Solutions, Inc. $61.98 2
ABBVIE INC. $22.63 1
Genentech USA, Inc. $15.37 1
Alimera Sciences, Inc. $14.27 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID L JOHNSON

NPI 1811942527 · CMS profile ID 127979

Allopathic & Osteopathic Physicians / Ophthalmology / Retina Specialist

WEST COLUMBIA, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1811942527?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID L JOHNSON, NPI 1811942527, CMS profile ID 127979. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811942527?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). DAVID L JOHNSON, NPI 1811942527, CMS profile ID 127979. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811942527?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
DAVID L JOHNSON, NPI 1811942527, CMS profile ID 127979, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1811942527?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $210.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $32.5412/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114078718 CMS
Regeneron Healthcare Solutions, Inc. $29.4409/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114078716 CMS
Genentech USA, Inc. $15.3708/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132997523 CMS
Ocular Therapeutix, Inc. $96.6606/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148197963 CMS
ABBVIE INC. $22.6305/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104001175 CMS
Alimera Sciences, Inc. $14.2704/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092826279 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $70.29 3
PY2020 $54.88 3
PY2021 $32.81 2
PY2022 $236.12 12
PY2023 $89.13 4
PY2024 $210.91 6
PY2025 $156.88 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,302,777.86 785
PY2024 Principal investigator $70,100.10 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

785 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ocular Therapeutix, Inc. $3,463.46 12/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235987
Principal investigator 1 Ocular Therapeutix, Inc. $24,609.00 12/24/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235973
Principal investigator 1 Ocular Therapeutix, Inc. $2,835.00 12/24/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279768
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279770
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279772
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11.48 12/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279774
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6.02 12/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279776
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.20 12/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279778
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7.42 12/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279780
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22.40 12/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279782
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6.02 12/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279784
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.48 12/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279786
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7.42 12/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279788
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271503
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,120.85 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271615
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271625
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271649
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271651
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271707
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184271717
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/27/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 11/27/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 11/27/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/27/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/27/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 11/27/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265775
Principal investigator 1 Ocular Therapeutix, Inc. $12,119.00 11/26/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235902
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/24/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184264109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/24/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184264111
Principal investigator 1 Ocular Therapeutix, Inc. $13,933.00 11/21/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11.48 11/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184263079
Principal investigator 1 Ocular Therapeutix, Inc. $54.00 11/19/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235876
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.20 11/19/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184262141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,120.85 11/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184261585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,120.85 11/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184261587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 11/14/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/14/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/14/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 11/14/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/14/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/14/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 11/14/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/14/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 11/14/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 11/14/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260751
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/14/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260753
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 11/14/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/14/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260757
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 11/14/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 11/14/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/14/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 11/14/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 11/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 11/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 11/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.48 11/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260299
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14.98 11/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260301
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184260305
Principal investigator 1 Ocular Therapeutix, Inc. $4,430.50 11/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235868
Principal investigator 1 Ocular Therapeutix, Inc. $540.00 11/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235872
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6.02 11/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184259533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6.02 11/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184259535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11.48 11/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184259537
Principal investigator 1 Ocular Therapeutix, Inc. $743.00 11/07/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235852
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/06/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184257615
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/06/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184257617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/06/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184257619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/06/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184257621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/06/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184257623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/06/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184257625
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254751
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,917.35 10/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254753
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,917.35 10/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254757
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22.40 10/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.60 10/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184253116
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7.42 10/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184253118
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251710
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251712
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251714
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 10/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251716
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251718
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251720
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251722
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251724
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251726
Principal investigator 1 Ocular Therapeutix, Inc. $18.48 10/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235822
Principal investigator 1 Ocular Therapeutix, Inc. $203.00 10/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235826
Principal investigator 1 Ocular Therapeutix, Inc. $7,592.00 10/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235836
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.48 10/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251033
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.20 10/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.60 10/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6.02 10/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6.02 10/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14.98 10/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11.48 10/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251065
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 10/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235999
Principal investigator 1 Ocular Therapeutix, Inc. $405.00 10/10/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/10/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/10/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 10/10/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/10/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249681
Principal investigator 1 Ocular Therapeutix, Inc. $87,217.00 10/08/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235788
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/08/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184247730
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/08/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184247734
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.20 10/08/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184247738
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.20 10/08/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184247740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22.40 10/08/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184247744
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.20 10/08/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184247746
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.20 10/08/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184247750
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.20 10/08/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184247756
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,917.35 10/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,917.35 10/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7.42 09/25/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14.98 09/25/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $796.50 09/24/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184242054
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241242
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241244
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241246
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241248
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238308
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238310
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 09/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238312
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238314
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238316
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238318
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,917.35 09/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238320
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238322
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6.02 09/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238324
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21.70 09/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238326
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6.02 09/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238328
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11.48 09/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238330
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.48 09/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238332
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.48 09/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238334
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14.98 09/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238336
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6.02 09/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238338
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6.02 09/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238340
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7.42 09/17/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238342
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184237422
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 09/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184237424
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 09/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184237426
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 09/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184237428
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184237430
Principal investigator 1 Ocular Therapeutix, Inc. $250.00 09/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236299
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236301
Principal investigator 1 Ocular Therapeutix, Inc. $3,469.22 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235710
Principal investigator 1 Ocular Therapeutix, Inc. $15,637.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235714
Principal investigator 1 Ocular Therapeutix, Inc. $5,000.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235718
Principal investigator 1 Ocular Therapeutix, Inc. $1,790.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234263
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234265
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234269
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234299
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234301
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234351
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234353
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234355
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234357
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234363
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234369
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,052.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.01 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234375
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234381
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234383
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234385
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234387
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231497
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231503
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184231553
Principal investigator 1 Ocular Therapeutix, Inc. $2,835.00 08/27/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235690
Principal investigator 1 Ocular Therapeutix, Inc. $1,790.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235678
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227195
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227401
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227403
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227411
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227413
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227421
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227425
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227439
Principal investigator 1 Ocular Therapeutix, Inc. $33.00 08/06/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235649
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224534
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224536
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,793.15 08/06/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224580
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224582
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224584
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224586
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224588
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224590
Principal investigator 1 Ocular Therapeutix, Inc. $57.75 08/01/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235628
Principal investigator 1 Ocular Therapeutix, Inc. $1,431.00 08/01/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235632
Principal investigator 1 Ocular Therapeutix, Inc. $827.55 07/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235620
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21.70 07/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184221770
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21.70 07/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184221772
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21.70 07/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184221774
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6.02 07/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184221776
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6.02 07/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184221778
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14.98 07/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184221780
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14.98 07/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184221782
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.48 07/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184221784
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.48 07/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184221786
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.48 07/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184221788
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7.42 07/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184221790
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7.42 07/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184221792
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26.60 07/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184221794
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11.48 07/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184221796
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11.48 07/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184221798
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6.02 07/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184221800
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6.02 07/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184221802
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $720.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222122
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,680.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222124
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $504.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222126
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $882.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222128
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $474.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222130
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,205.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222132
Principal investigator 1 Ocular Therapeutix, Inc. $8,505.00 07/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235588
Principal investigator 1 Ocular Therapeutix, Inc. $16,916.00 07/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235539
Principal investigator 1 Ocular Therapeutix, Inc. $233.00 07/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235544
Principal investigator 1 Ocular Therapeutix, Inc. $16,916.00 07/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235549
Principal investigator 1 Ocular Therapeutix, Inc. $16,916.00 07/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235554
Principal investigator 1 Ocular Therapeutix, Inc. $16,916.00 07/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235572
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215328
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215330
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215332
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215336
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215338
Principal investigator 1 Ocular Therapeutix, Inc. $2,835.00 07/02/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235468
Principal investigator 1 Ocular Therapeutix, Inc. $250.00 06/18/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235432
Principal investigator 1 Ocular Therapeutix, Inc. $14,131.52 06/11/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235420
Principal investigator 1 Ocular Therapeutix, Inc. $1,790.00 06/04/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/02/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184200795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.25 06/02/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184200799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 06/02/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184200835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201979
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 06/02/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 06/02/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 06/02/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 06/02/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 06/02/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 06/02/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 06/02/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202675
Principal investigator 1 Ocular Therapeutix, Inc. $1,790.00 05/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235388
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $661.50 05/28/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184199277
Principal investigator 1 Ocular Therapeutix, Inc. $56,533.00 05/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235365
Principal investigator 1 Ocular Therapeutix, Inc. $7,000.00 05/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235379
Principal investigator 1 Ocular Therapeutix, Inc. $4,532.00 05/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235384
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5.76 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13.40 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21.44 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21.44 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21.44 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5.76 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21.44 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16.08 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.69 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5.76 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.69 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14.74 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.46 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5.76 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13.40 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13.40 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13.13 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16.08 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.46 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.69 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13.13 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.03 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.69 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14.74 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5.76 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16.08 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8.98 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.03 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13.40 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.03 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8.98 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16.08 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8.98 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.46 05/22/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198127
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195351
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195353
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195355
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195363
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195369
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195375
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195381
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195383
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195385
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195389
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195391
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195393
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195395
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195401
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195411
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195413
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195421
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195425
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195497
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195503
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184195511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 05/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184194333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 05/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184194335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 05/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184194337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 05/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184194339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 05/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184194341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 05/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184194343
Principal investigator 1 Ocular Therapeutix, Inc. $2,835.00 04/30/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235351
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186845
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186859
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186863
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186869
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186873
Principal investigator 1 Ocular Therapeutix, Inc. $1,790.00 04/18/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235335
Principal investigator 1 Ocular Therapeutix, Inc. $1,240.65 04/16/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235324
Principal investigator 1 Ocular Therapeutix, Inc. $250.00 04/09/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235311
Principal investigator 1 Ocular Therapeutix, Inc. $250.00 04/09/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181432
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181434
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181436
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181438
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181440
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181442
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181444
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181446
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181448
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181450
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181452
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181454
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181456
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181458
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181460
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181462
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181464
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181466
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181468
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181470
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181472
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181474
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181476
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181478
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 04/03/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184181480
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178178
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178180
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178182
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178184
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178186
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178188
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178190
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178192
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178194
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178196
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178198
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178200
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178202
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178204
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178206
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178208
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178330
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178332
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178334
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178336
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178338
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178340
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178342
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178344
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178346
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178348
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178350
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178352
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178354
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178356
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178358
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178360
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178458
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/20/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184178460
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173422
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173424
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173426
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173428
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173430
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173432
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173434
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173436
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173438
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173440
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173442
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173444
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173480
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173482
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173484
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173486
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173488
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173490
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173492
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173494
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173496
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173498
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173500
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173502
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173504
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173506
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173508
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173510
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173542
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173544
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173546
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173548
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173550
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173552
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173554
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173556
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173558
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173560
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173562
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173564
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173566
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173568
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173570
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184173572
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $796.50 02/10/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184152922
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $661.50 02/10/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184152924
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $796.50 02/10/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184152926
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7.64 02/10/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184152928
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7.64 02/10/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184152930
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7.64 02/10/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184152932
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7.64 02/10/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184152934
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7.64 02/10/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184152936
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7.64 02/10/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184152938
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7.64 02/10/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184152940
Principal investigator 1 Ocular Therapeutix, Inc. $5,670.00 01/24/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250235281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146266
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146268
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146270
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146272
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146274
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146276
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 01/08/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146278
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146280
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146282
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
PALMETTO RETINA CENTER LLC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184146284